Medicine guide
Vitekta
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Elvitegravir
- Made by
- Gilead Sciences International Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Gilead Sciences International Ltd |
|---|---|
| Active substance | Elvitegravir |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AX11 · Antibiotics, antivirals and antifungals taken into the body |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2013-11-13 |
| Last updated by the regulator | 2017-05-29 |
| EMA product number | EMEA/H/C/002577 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).